Success Story: Our Firm Assisted a Bangladeshi Researcher In Securing An NIW Success Without RFE
Client’s Testimonial:
"Thank you very much for your support and guidance throughout my NIW I-140 petition process. I truly appreciate your professional service. I am satisfied with the overall case preparation process. The team was professional, efficient, and communicated clearly throughout. Thank you again for your excellent service!"
On April 17th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Graduate Research Assistant in the Field of Pharmacy (Approval Notice).
General Field: Pharmacy
Position at the Time of Case Filing: Researcher/Evaluator
Country of Origin: Bangladesh
State of Residence at the Time of Filing: Northern Mariana Islands
Approval Notice Date: April 17th, 2026
Processing Time: 14 months, 27 days (Premium Processing Upgrade Requested)
Case Summary:
When a case centers on chronic diseases as widespread as obesity, diabetes, and cancer, the challenge is not merely to show that the research is scientifically interesting. The stronger argument is that the work addresses a public health problem broad enough to matter nationally and that the researcher has already shown the ability to move that work forward. That was the approach in this client’s I-140 NIW case. The client, Ph.D. in Pharmacy (Pharmaceutical Technology), was presented as a researcher in pharmacy whose proposed endeavor focuses on identifying bioactive compounds and molecular mechanisms that modulate the factors responsible for obesity, diabetes, and cancer in order to develop effective therapeutic strategies. The petition explained that this work had substantial merit and national importance because it addressed major chronic disease burdens and aligned with U.S. interests in public health and biotechnology.
The publication record supported that point. The client had authored 22 peer-reviewed journal articles, including 6 first-authored papers and 1 corresponding-authored paper, as well as 3 abstracts and 1 book chapter. The petition did not ask USCIS to treat those numbers as automatically persuasive. Instead, it explained why the record mattered: the work had appeared in respected journals, covered multiple relevant areas within pharmacy and therapeutic development, and showed sustained scholarly productivity tied to the proposed endeavor.
The citation evidence was even more important. The client’s work had been cited 261 times, but the filing did not stop at that raw number. It contextualized the citations through field and year comparisons, showing that multiple papers were performing well above expected citation averages. According to the petition, 2 papers ranked among the top 1% most cited for their publication year, 2 ranked in the top 10%, and 4 ranked in the top 20% in Pharmacology & Toxicology. That kind of normalized evidence is often more persuasive than a bare citation total because it shows that other researchers were relying on the client’s work at an unusually high rate for the field.
The case further showed professional recognition through peer review. The client had completed at least 7 reviews for journals in relevant areas, which supported the argument that editors viewed the client as someone qualified to judge the work of other researchers. In an NIW case, that kind of evidence helps show expertise and standing in the field, especially when paired with publication and citation data.
Overall, this approval reflected a case strategy built on more than credentials alone. The petition connected the client’s training, ongoing employment, publication history, citation impact, and peer review service into a clear argument that the client was well-positioned to continue research of national importance. We are delighted that the client’s I-140 NIW petition was approved and wish them continued success in the United States.